Premium
Use of multi‐cell spheroids of ovarian carcinoma as an intraperitoneal radio‐immunotherapy model: Uptake, retention kinetics and dosimetric evaluation
Author(s) -
Bardiès Manuel,
Thedrez Philippe,
Gestin JeanFrancois,
Marcille BertheMarie,
Guerreau Dominique,
FaivreChauvet Alain,
Mahe Marc,
SaiMaurel Catherine,
Chatal JeanFrançois
Publication year - 1992
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.2910500627
Subject(s) - spheroid , kinetics , penetration (warfare) , radioimmunotherapy , immunotherapy , monoclonal antibody , nuclear medicine , ovarian carcinomas , chemistry , ovarian carcinoma , cancer research , in vitro , medicine , antibody , immunology , ovarian cancer , cancer , physics , biochemistry , quantum mechanics , operations research , engineering
The purpose of this study, using multi‐cell spheroids as an in vitro model of micrometastases of ovarian carcinoma for i.p. radio‐immunotherapy, was to measure the uptake and retention kinetics of 'In‐labeled F(ab') 2 fragments of OCI25 monoclonal antibody (MAb) in spheroids of the NIH:OVCAR‐3 cell line and to estimate absorbed doses with beta‐emitting radionuclides (kinetics was assumed to be similar to that of indium‐111). With 0.2‐mm‐diameter spheroids at different MAb concentrations the highest binding value was determined. Retention kinetics showed a biological half‐life of 50 hr. These data were used to calculate absorbed doses by integration of Berger's latest‐point kernels. Mean absorbed doses when spatial distribution was considered to be uniform at the surface (no penetration) or throughout the spheroid (total penetration) were, respectively, 247 and 417 Gy with 153 Sm, and 90 and 135 Gy with 90 Y. Thus, the use of a similar MAb concentration and specific activity in patients should lead to high absorbed doses in i.p. radio‐immunotherapy of micrometastases.